Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carvedilol
Drug ID BADD_D00374
Description Carvedilol is a racemic mixture where the S(-) enantiomer is a beta adrenoceptor blocker and the R(+) enantiomer is both a beta and alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.[A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889]
Indications and Usage Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.[L7889,L7892]
Marketing Status approved; investigational
ATC Code C07AG02
DrugBank ID DB01136
KEGG ID D00255
MeSH ID D000077261
PubChem ID 2585
TTD Drug ID D0W9LX
NDC Product Code 72888-034; 72888-035; 76385-112; 0904-6302; 55111-030; 65862-144; 68294-0005; 0093-7295; 43063-833; 50090-4171; 55154-5676; 55154-5678; 65862-143; 68788-7539; 68788-8177; 71335-0273; 71335-1813; 71335-1937; 76385-111; 76385-113; 0781-5223; 43063-126; 51079-771; 51079-932; 51407-040; 51655-034; 51655-943; 58118-0163; 60760-376; 63187-570; 63187-946; 68001-153; 68084-854; 68788-8151; 70518-3524; 71335-2026; 71335-2033; 65691-0087; 35356-512; 35356-526; 43353-838; 50090-4898; 51407-042; 53002-1572; 55154-7278; 60760-582; 61919-730; 61919-984; 63187-447; 0378-3631; 65841-617; 65841-618; 68001-151; 68071-3138; 68071-5275; 68788-9789; 71335-1128; 71335-1545; 55154-5677; 61919-219; 61919-728; 0378-3633; 0378-3634; 68001-152; 68071-2633; 68071-2773; 68788-7458; 68788-7603; 69784-141; 70934-753; 71335-2101; 71610-066; 72888-036; 0904-6300; 43353-832; 50090-2066; 51407-041; 51655-397; 51655-713; 60760-233; 63187-424; 63187-941; 68382-094; 68382-095; 68645-496; 69784-139; 70518-1826; 71610-132; 0615-8390; 0904-6301; 65862-142; 43353-874; 50090-2175; 51655-029; 51655-030; 55111-252; 60760-532; 68001-154; 68462-162; 71335-1457; 71335-1463; 71335-2023; 71610-067; 0615-8389; 72888-037; 52932-0726; 53104-7575; 64220-150; 0093-7296; 42708-072; 43063-129; 50090-1069; 50090-2079; 55111-253; 55111-255; 55154-5675; 68071-2780; 68382-092; 68462-163; 68462-165; 68645-350; 68788-8252; 69784-142; 70934-211; 71335-1407; 72189-372; 0615-8387; 0615-8388; 57451-1155; 65862-145; 65862-369; 0093-0051; 55154-6883; 63187-409; 68462-164; 68645-351; 68788-8231; 70518-1377; 70518-3640; 70934-910; 71610-062; 0781-5221; 66022-0120; 72761-004; 0093-0135; 43353-837; 50090-1856; 51655-033; 55154-6884; 61919-533; 63629-4060; 65841-616; 65841-619; 68071-2230; 68382-093; 68788-7910; 69784-140; 71335-1623; 71610-063; 76385-110; 0781-5224; 0904-6303; 42419-013; 43063-125; 51079-930; 51079-931; 51407-039; 55154-6885; 55700-819; 60760-494; 63187-131; 0378-3632; 67296-1497; 68788-9265; 70518-0356; 70518-0426; 70934-874; 71335-1533; 0781-5222; 47621-064; 0007-4142; 53002-1556; 53002-1573; 53002-1574; 55111-254
UNII 0K47UL67F2
Synonyms Carvedilol | Carvedilol Hydrochloride | Dilatrend | Querto | Eucardic | Carvedilol, (S)-isomer | Kredex | BM 14190 | BM-14190 | BM14190 | Carvedilol, (R)-isomer | Carvedilol, (+)-isomer | Carvedilol, (+) | Carvedilol, (+-)-isomer | Carvedilol, (-)-isomer | Carvedilol, (-) | Carvedilol, 14C-labeled | 14C-labeled Carvedilol | Carvedilol, 14C labeled | Coropres | Coreg
Chemical Information
Molecular Formula C24H26N2O4
CAS Registry Number 72956-09-3
SMILES COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Erythema multiforme10.01.03.015; 23.03.01.003--
Extrasystoles02.03.02.003---
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.0040.000056%
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Feeling cold08.01.09.008---
Flatulence07.01.04.002--
Fluid retention14.05.06.002; 20.01.02.003---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.0020.000041%
Gamma-glutamyltransferase increased13.03.04.024--
Gastrointestinal disorder07.11.01.001---
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009---
Gastrointestinal pain07.01.05.005--
Generalised oedema08.01.07.004; 14.05.06.007--
Glucose tolerance impaired05.06.02.001; 14.06.02.001--
Glycosuria20.02.01.005--
Gout14.09.01.001; 15.01.06.001---
Gravitational oedema02.05.04.014; 08.01.07.005---
Haemangioma16.02.01.002; 24.03.06.0040.000021%-
Haematochezia07.12.02.003; 24.07.02.0120.000046%-
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Haemoglobin13.01.05.018---
Haemorrhage intracranial17.08.01.008; 24.07.04.0030.000052%
Hallucination19.10.04.0030.000041%
Hallucination, visual19.10.04.0070.000021%-
Headache17.14.01.0010.000309%
Hepatic encephalopathy09.01.03.006; 17.13.01.0030.000052%-
Hepatic failure09.01.03.0020.000041%
Hepatic function abnormal09.01.02.0010.000041%-
High density lipoprotein decreased13.12.01.003---
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 12 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene